depemokimab
Jump to navigation
Jump to search
Indications
Dosage
- 100 mg subcutaneously twice yearly
Mechanism of action
- binds to & inhibits interleukin-5
More general terms
References
- ↑ Jackson DJ et al Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. N Engl J Med 2024. Sept 9 PMID: https://www.ncbi.nlm.nih.gov/pubmed/39248309 https://www.nejm.org/doi/full/10.1056/NEJMoa2406673
- ↑ Gevaert P et al. Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): Phase 3, randomised, double-blind, parallel trials. Lancet 2025 Feb 28; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/40037388 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00197-7/abstract